Barrow, Hanley, Mewhinney & Strauss
EVH icon

Barrow, Hanley, Mewhinney & Strauss’s Evolent Health EVH Stock Holding History

Barrow, Hanley, Mewhinney & Strauss’s Portfolio EVH Stock Details EVH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-236
Closed -$2.66K – 359
2025
Q2 		$2.66K Buy
236
+180
+321% +$1.65K ﹤0.01% 286
2025
Q1 		$530 Buy
+56
New +$566 ﹤0.01% 316

Other funds holding EVH

CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
RF
Rubicon Founders Nashville, Tennessee $138M AUM 61.96% 1-Year Est. Return
EC
Engaged Capital Newport Beach, California $303M AUM 2.09% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss's EVH Position: Q3 2025 in Review

Barrow, Hanley, Mewhinney & Strauss sold out of Evolent Health (EVH) in Q3 2025, closing a stake of 236 shares — an estimated $2.66K sold.

Barrow, Hanley, Mewhinney & Strauss first reported a position in EVH in Q1 2025 and held it in 2 quarters. The position peaked at $2.66K in Q2 2025. 240 funds tracked by Wall St. Rank hold EVH as of Q3 2025.

  • Barrow, Hanley, Mewhinney & Strauss reported no remaining Evolent Health position as of Q3 2025 after selling out during the quarter.
  • Barrow, Hanley, Mewhinney & Strauss sold 236 Evolent Health shares in Q3 2025, an estimated $2.66K.
  • Barrow, Hanley, Mewhinney & Strauss first reported a position in Evolent Health in Q1 2025 and held it in 2 quarters.
  • Barrow, Hanley, Mewhinney & Strauss's Evolent Health position peaked at $2.66K in Q2 2025.
  • 240 funds tracked by Wall St. Rank held Evolent Health as of Q3 2025.

Based on Barrow, Hanley, Mewhinney & Strauss's 13F filing for Q3 2025, filed 13 Nov 2025.